High Blood Pressure: Clinical Trials

10 trials for High Blood Pressure, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 2 withdrawn. 10 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 410Completed 8, Withdrawn 2

Follow High Blood Pressure: new trials by email Literature Review of High Blood Pressure trials Research Report on High Blood Pressure

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)
Amlodipine Besylate, Chlorthalidone - High Blood Pressure, Liver Transplant
Phase 4WithdrawnNorthwestern University2022-07-122023-10-13
Treating Nocturnal Hypertension and Nocturia in African American Men
Thiazide Treatment Group, Intensified Thiazide Treatment Group, Combination Medication Treatment Group - High Blood Pressure
Phase 4WithdrawnCedars-Sinai Medical Center2017-10-252021-02-04
Intensive Vasodilator Therapy in Patients With Essential Hypertension
Amlodipine, Ramipril, Lercanidipine - Essential Hypertension, High Blood Pressure
Phase 4CompletedAarhus University Hospital482010-12-012012-04-19
A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.
Aliskiren and HCTZ - High Blood Pressure
Phase 4CompletedNovartis2532010-02-012017-02-23
The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension
Nebivolol, Metoprolol XL - High Blood Pressure
Phase 4CompletedEmory University912009-12-012017-04-11
The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function
Aliskiren 150 mg, Placebo, HCTZ - High Blood Pressure
Phase 4CompletedVanderbilt University Medical Center312009-06-012017-08-25
To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone
Amlodipine 5mg/Valsartan 80 mg, Valsartan - Hypertension, High Blood Pressure
Phase 4CompletedNovartis602009-06-012011-10-19
Magnesium and Metabolic Syndrome
Magnesium chloride, Placebo - Diabetes Mellitus, High Blood Pressure
Phase 4CompletedInstituto Mexicano del Seguro Social852006-07-012008-01-29
Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension
Bunazosin, Doxazosin, Valsartin - High Blood Pressure
Phase 4CompletedEisai Inc.932005-10-012013-05-14
ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)
losartan potassium, Comparator: Placebo - High Blood Pressure
Phase 4CompletedOrganon and Co3672000-03-142024-08-15

Narrower conditions

Hypertension (10)  ·  Cardiovascular Diseases (1)  ·  Diabetes Mellitus (1)  ·  Essential Hypertension (1)  ·  Vascular Diseases (1)

Broader conditions

Cardiovascular Diseases (9)  ·  Vascular Diseases (9)  ·  Endocrine System Diseases (1)  ·  Glucose Metabolism Disorders (1)  ·  Metabolic Diseases (1)  ·  Nutritional and Metabolic Diseases (1)

Interventions

Amlodipine (3)  ·  Hydrochlorothiazide (2)  ·  Losartan (2)  ·  Valsartan (2)  ·  aliskiren (2)  ·  Amlodipine, Valsartan Drug Combination (1)  ·  Chlorthalidone (1)  ·  Doxazosin (1)  ·  Magnesium Chloride (1)  ·  Metoprolol (1)  ·  Nebivolol (1)  ·  Ramipril (1)  ·  bunazosin (1)  ·  lercanidipine (1)

Sponsors

Novartis (2)  ·  Aarhus University Hospital (1)  ·  Cedars-Sinai Medical Center (1)  ·  Eisai Inc. (1)  ·  Emory University (1)  ·  Instituto Mexicano del Seguro Social (1)  ·  Northwestern University (1)  ·  Organon and Co (1)  ·  Vanderbilt University Medical Center (1)

Countries

United States (4)  ·  Taiwan (2)  ·  Denmark (1)  ·  Mexico (1)  ·  Venezuela (1)

Top investigators

Ashkan Eftekhari, MD, PhD (1)  ·  Dempsey Hughes, MD (1)  ·  Martha Rodriguez-Moran, MD, MSc, PhD (1)  ·  Morten Engholm Pedersen, MD (1)  ·  Niels Henrik Buus, DMSc (1)  ·  Ole Norling Mathiasen, MD, PhD (1)  ·  Ya-hui Cheng (1)

Results publications

PMID 26285691, PMID 39082471

NIH funding

R56HL155093 (1)